Notes to the consolidated financial statements

1. BASIS OF PREPARATION

1.1 INTRODUCTION
 

The summarised audited consolidated annual financial statements for the year ended 30 June2019 have been prepared in compliance with the Listings Requirements of the JSE Limited, International Financial Reporting Standards (IFRS), the requirements of the International Accounting Standards (IAS) 34: Interim financial reporting, SAICA Financial Reporting Guidelines as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council and the Companies Act, No. 71 of 2008. These condensed results for the year ended 30 June 2019, extracted from the audited consolidated financial statements, which the Board of directors take full responsibility for, have been prepared by Ms Dorette Neethling, Chief Financial Officer. Both these summarised results and the consolidated financial statements were audited by the independent external auditors, Ernst & Young Inc. and copies of their unqualified audit opinions are available for inspection at the Company’s registered office.

1.2 CHANGES IN ACCOUNTING POLICIES
 

The accounting policies adopted are consistent with those of the previous financial year except for the adoption of the following new and amended IFRS standards and interpretations during the year, which did not have a significant impact on the financial performance or position of the Group:

IFRS 9: Financial instruments – recognition and measurement

IFRS 9 is the new financial instrument accounting standard and includes the requirements for classification and measurement of financial assets, the impairment and derecognition of financial assets, as well as general hedge accounting.

The classification and measurement of the Group’s financial assets are substantially the same as under IAS 39, except for:

  • the reclassification of the long-term receivable from the Black Managers Share Trust, from amortised cost to fair value through profit or loss; and
  • the measurement of the expected credit loss for trade receivables.

In measuring the provision for trade receivables, the Group has applied the new rules using the modified retrospective approach, whereby the financial statements are retrospectively adjusted and the cumulative impact (a reduction of R4.4 million after tax) was recorded on 1 July 2018, the initial date of implementing the standard, by recognising an adjustment to opening retained earnings. A simplified impairment approach was used, whereby the lifetime expected losses on trade receivables are recorded immediately.

The Group has chosen to continue to apply the hedge accounting requirements of IAS 39, instead of the requirements in IFRS 9, to all of its hedging relationships.

IFRS 15: Revenue from contracts with customers

IFRS 15 establishes a five-step model for entities to use in accounting for revenue arising from contracts with customers. The new standard is based on the principle that revenue is recognised at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to a customer. The new standard supersedes all current revenue recognition requirements under IFRS.

The Group adopted IFRS 15 using the retrospective approach, with the following impact on the Group’s financial statements:

  • disaggregated revenue disclosure; and
  • liabilities for the non-performance on customer contracts will be recognised against revenue.

2. REVENUE

 
  Audited
2019
R’000
  Audited
2018
R’000
 
Contracts with customers 7 078 438   6 382 706  
Finance income 6 756   18 270  
Dividend income – Black Managers Share Trust 3 864   4 340  
  7 089 058   6 405 316  
Contracts with customers by channel  Private  Public  Export and 
foreign
 
Total    
30 June 2019                
Continuing operations:                
Southern Africa  5 969 909  863 346  196 779  7 030 034    
   OTC  1 820 678  117 176  45 032  1 982 886    
   Prescription  2 355 191  319 832  64 626  2 739 649    
   Consumer  737 800  49 092  786 896    
   Hospital  990 241  426 334  38 029  1 454 604    
   Other – shared services  65 999        65 999    
Rest of Africa        68 524  68 524    
Research and development services in India        21 114  21 114    
Less: Inter-company sales        (41 234) (41 234)   
   5 969 909  863 346  245 183  7 078 438    

Most of the Group’s revenue from contracts with customers is recognised at a point in time.

3. NON-TRADING EXPENSES

 
  Audited
2019
R’000
  Audited
2018
R’000
 
Impairments 8 568   5 235  
Fair value adjustment of long-term receivable 1 763    
Transaction costs 5 843   7 315  
Retrenchment costs 12 347    
Share-based payment expenses 41 756   34 345  
Release of foreign currency translation reserve on disposal of investment in associate 1 607    
  71 884   46 895  

4. DISCONTINUED OPERATION

 

The Group disposed of its interest in Pharmalabs (Jersey) Limited, the owner of Datlabs Proprietary Limited (Datlabs) in Zimbabwe. The results of Datlabs are presented below.

4.1 STATEMENT OF COMPREHENSIVE INCOME
 
   Audited 
2019 
6 months 
R'000 
   Audited 
2018 
12 months 
R'000 
  
Revenue  86 261     157 549    
Contracts with customers  86 261     157 549    
Cost of sales  (61 165)    (102 838)   
Gross profit  25 096     54 711    
Selling, distribution and marketing expenses  (11 374)    (21 799)   
Fixed and administrative expenses  (8 803)    (16 479)   
Trading profit  4 919     16 433    
Non-trading expenses (note 4.2) (1 821)    –    
Operating profit  3 098     16 433    
Finance costs  –     (786)   
Profit before taxation  3 098     15 647    
Taxation  (1 115)    (4 939)   
Profit for the period/year from discontinued operation  1 983     10 708    
Loss on disposal of the discontinued operation  (3 592)    –    
(Loss)/Profit for the period/year from discontinued operation attributable to owners of the parent  (1 609)    10 708    
4.2 NON-TRADING EXPENSES
 
  Audited 
2019 
6 months 
R'000 
   Audited 
2018 
12 months 
R'000 
  
Transaction costs 1 821    
4.3 CASH INFLOW ON DISPOSAL
 
   Audited 
2019 
6 months 
R'000 
   Audited 
2018 
12 months 
R'000 
  
Consideration received  36 185          
Net cash disposed of with the discontinued operation  (20 245)         
Net cash inflow  15 940          
4.4 CASH FLOW STATEMENT
 
   Audited 
2019 
6 months 
R'000 
   Audited 
2018 
12 months 
R'000 
  
Included in the Group’s consolidated statement of cash flows are cash flows from the Zimbabwean             
discontinued operation. These cash flows are included in the statements of cash flows as follows:             
Cash (outflow)/inflow from operating activities  (3 631)    40 165    
Cash outflow from investing activities  (7 264)    (7 964)   
Cash outflow from financing activities  –     (1 881)   
Net cash (outflow)/inflow  (10 895)    30 320    

5. SEGMENT REPORTING

 
   Audited 
2019 
R'000 
   Audited 
2018 
R'000 
  
Revenue from contracts with customers             
Continuing operations            
Southern Africa  7 030 034      6 338 389    
   OTC  1 982 886     1 989 225    
   Prescription  2 739 649     2 237 620    
   Consumer  786 896     686 699    
   Hospital  1 454 604     1 347 698    
   Other – shared services  65 999     77 147    
Rest of Africa  68 524     65 075    
Research and development services in India  21 114     19 494    
   7 119 672     6 422 958    
Less: Intercompany sales  (41 234)    (40 252)   
   7 078 438     6 382 706    
Discontinued operation            
Rest of Africa  86 261     157 549    
         
Trading and operating profit             
Continuing operations             
Southern Africa  944 752     845 540    
   OTC  388 361     399 640    
   Prescription  309 989     239 435    
   Consumer  134 177     112 181    
   Hospital  112 225     95 312    
   Other – shared services  –     (1 028)   
Rest of Africa  8 609     1 897    
Research and development services in India  2 060     2 507    
Trading profit  955 421     849 944    
Less: Non-trading expenses  (71 884)    (46 895)   
Operating profit  883 537     803 049    
Discontinued operation – Rest of Africa             
Trading profit  4 919     16 433    
Less: Non-trading expenses  (1 821)    –    
Operating profit  3 098     16 433    
         
Total assets             
Southern Africa  5 922 443     5 844 806    
   OTC  1 771 142     1 761 603    
   Prescription  2 020 144     1 987 006    
   Consumer  342 209     315 425    
   Hospital  1 189 750     1 236 482    
   Other – shared services  599 198     544 290    
Rest of Africa  40 502     163 141    
India  287 848     262 778    
   6 250 793     6 270 725    

6. INVENTORY

 
  Audited
2019
R’000
  Audited
2018
R’000
 
Inventories written down and recognised as an expense in cost of sales in profit or loss:        
Continuing operations 99 944   91 466  
Discontinued operation 290   3 388  
  100 234   94 854  

7. CAPITAL COMMITMENTS

 
  Audited
2019
R’000
  Audited
2018
R’000
 
– Contracted for 21 772   32 932  
– Approved but not contracted 90 100   63 258  
  111 872   96 190  

8. HEADLINE EARNINGS

 
   Audited 
2019 
R'000
 
   Audited 
2018 
R'000 
  
Headline earnings is determined as follows:             
Continuing operations             
   Earnings attributable to owners of Adcock Ingram from total operations  687 986     637 943    
   Adjusted for:             
   Loss/(Profit) attributable to Adcock Ingram from discontinued operation (note 4.1) 1 609     (10 708)   
   Earnings attributable to owners of Adcock Ingram from continuing operations  689 595      627 235    
   Adjusted for:             
   Impairment of intangible assets  5 595      2 700    
   Impairment of investment in associate  2 973      –    
   Release of foreign currency translation reserve on disposal of investment in associate  1 607      –    
   Loss/(Profit) on disposal/scrapping of property, plant and equipment  677      (1 968)   
   Tax effect on loss/(profit) on disposal of property, plant and equipment  (257)      (42)   
   Adjustments relating to equity accounted joint ventures and associate             
      Impairment of goodwill  –      5 312    
      Loss on disposal of long-term receivable  –      828    
      Loss/(Profit) on disposal of property, plant and equipment  1 290      (24)   
      Tax effect on loss on disposal of property, plant and equipment  (445)      –    
Headline earnings from continuing operations  701 035      634 041    
Discontinued operation             
(Loss)/Profit attributable to owners of Adcock Ingram from discontinued operation  (1 609)      10 708    
Adjusted for:  –      –    
Loss on sale of discontinued operation (note 4.1) 3 592      –    
Headline earnings from discontinued operation  1 983      10 708    

9. SHARE CAPITAL

 
   '000     '000    
Number of shares in issue  175 748     175 748    
Number of ordinary shares held by Group companies  (4 324)    (4 292)   
Net shares in issue  171 424     171 456    
Headline earnings and basic earnings per share are based on:             
Weighted average number of ordinary shares outstanding  166 260     166 293    
Diluted weighted average number of shares outstanding  166 262     166 295    

10. SUBSEQUENT EVENTS

 

ADCOCK INGRAM BROAD-BASED BLACK EMPOWERMENT SCHEME

Securities holders of AdBEE (RF) Limited (AdBEE) were notified on 31 May 2019 that AdBEE would not initiate the process of extending the Adcock Ingram Broad-Based Black Empowerment Scheme (Scheme) and accordingly the Scheme came to an end on 29 July 2019.

The value of a Scheme share did not exceed the maximum price (being R72.00) and therefore, on 1 August 2019, the Scheme transaction, in its entirety, was ipso facto cancelled ab initio.

The cancellation ab initio of the Scheme transaction had the effect that the Scheme shares held by Ad-izinyosi Proprietary Limited (Ad‑izinyosi) ceased to be subject to a pledge and were returned by Ad‑izinyosi to AdBEE securities holders.

The Mpho ea Bophelo Trust indirectly held 20% (5 168 592) of the Ad-izinyosi shareholding in Adcock Ingram Holdings Limited of 25 842 959 shares, which were treated as treasury shares for the purposes of calculating earnings per share (EPS) and headline earnings per share (HEPS). Following the cancellation of the Scheme, these shares will no longer be regarded as treasury shares.

11. FAIR VALUE HIERARCHY

 
            Year end balance     Net gains/
(losses)
  
Financial instruments  Classification per IFRS 9  Classification per IAS 39  Statement of financial position  2019 
R’000
 
   2018 
R’000 
   2019 
R’000
 
  
Investment(1)  Fair value through OCI  Available-for-sale  Other financial assets  1 649     1 937     35    
Black Managers Share Trust(1)  Fair value through profit and loss  Loans and receivables  Other financial assets  27 978     32 073     (1 763)   
Trade and sundry receivables(3)  At amortised cost  Loans and receivables  Trade and other receivables  1 679 475     1 535 369     –    
Foreign exchange contracts – derivative asset(2)  Fair value through OCI  Cash flow hedge  Trade and other payables       21 838     –    
Cash and cash equivalents(3)  At amortised cost  Loans and receivables  Cash and cash equivlents  448 252     404 629     –    
Trade and other payables (3)  At amortised cost  Loans and borrowings  Trade and other payables  1 605 575     1 830 652     –    
Foreign exchange contracts  – derivative liability(2)  Fair value through OCI  Cash flow hedge  Trade and other payables  16 799     –     (5 026)   
Bank overdraft(2)  At amortised cost  Loans and borrowings  Bank overdraft  –     248 877     –    
(1) Level 3. The value of the investment in Group Risk Holdings Proprietary Limited is based on Adcock Ingram’s proportionate share of the net asset value of the Company. The value of the investment in the Black Managers Share Trust is based on the capital contribution to be received from the scheme beneficiaries.
(2) Level 2. Fair value based on the ruling market rate at year-end. The fair value of the forward exchange contract as the difference in the forward exchange rate as per the contract and the forward rate of a similar contract with similar terms and maturities concluded as at the valuation date multiplied by the foreign currency monetary units as per the FEC contract.
(3) The carrying value approximates fair value.